
Cholestasis encompasses a range of conditions characterised by impaired bile flow, from intrahepatic causes such as primary biliary cholangitis to extrahepatic biliary obstruction. Pruritus and progressive fibrosis are major clinical concerns in chronic cholestatic liver diseases. Obeticholic acid, fibrates, and novel FXR agonists are expanding the therapeutic armamentarium beyond ursodeoxycholic acid.
